SenoRx, developer and manufacturer of minimally-invasive medical devices for breast cancer diagnosis, announced the terms for its IPO Wednesday. The company plans to offer 5,500,000 shares at a range of $11.00 to $13.00. Banc of America Securities and Citigroup are the joint lead managers on the deal.
